As with all licensed medicines, we will continue to monitor its safety closely as it becomes more widely used
Similar Posts
Field Safety Notices: 23-27 February 2026
List of Field Safety Notices from 23-27 February 2026.
Guidance: AI Airlock Sandbox Pilot Programme Report
The MHRA’s AI Airlock pilot phase ran between April 2024 and March 2025. This report does not constitute formal MHRA guidance.
Mirdametinib approved to treat plexiform neurofibromas in children, adolescents, and adults with neurofibromatosis type 1
As with any medicine, the MHRA will keep the safety and effectiveness of mirdametinib under close review.
Medicines: Get integrated scientific advice from the MHRA and NICE
Using the Integrated Scientific Advice service from the Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute for Health and Care Excellence (NICE).
Submission and assessment timetables for innovative medicines applications
Guidance on the deadlines for initial and response submissions.
MHRA Safety Roundup: August 2025
Summary of the latest safety advice for medicines and medical device users